Safety and Efficacy of Stem Cell Transplantation for Treatment of Liver Cirrhosis
Safety and Efficacy of Stem Cell Transplantation for Treatment of Liver Cirrhosis
Mainstream of current treatment of liver cirrhosis is liver transplantation, but there are
 high cost, risk and immune rejection and other issues. Umbilical cord mesenchyma stem cell
 with self-and directed differentiation capacity can effectively rescue experimental liver
 failure and contribute to liver regeneration, which suggests the feasibility of stem cell
 transplantation therapy. In this study, the safety and efficacy of umbilical cord mesenchyma
 stem cell transplantation through interventional procedures in patients liver cirrhosis will
 be evaluated.
This study included three research centers, each center were carried out 25 cases of liver
 cirrhosis in patients with stem cell transplantation. All the selection and exclusion
 criteria are same, data summary and analysis will be complete by the epidemiological
 commissioner.
Inclusion Criteria:

 -  Clinical diagnosis of liver cirrhosis;

 -  Without hepatic encephalopathy;

 -  No ascites or have easily dissipated ascites;

 -  Value of bilirubin is less than 100;

 -  Value of albumin is greater than 16 g / L;

 -  Prothrombin time is less than 21 seconds;

 Exclusion Criteria:

 -  Severe cardiovascular disease, and immunocompromised patients;

 -  Patients with localized lesions affecting graft infection;

 -  Coagulation disorders;

 -  Liver nodules more than 2cm or Liver cancer